Susan Jackson
Clinical Research Fellow
McShane Group
RESEARCH
I am a clinical research fellow and DPhil student working in both the Tuberculosis (TB) vaccine programme at the Jenner Institute and COVID-19 clinical research at the Oxford Vaccine Group in projects headed by Professor Helen McShane. I have additionally, worked on the COVID-19 vaccine trial team headed by Professor Andrew Pollard.
Since graduating from Nottingham University with a BMedSci(hons) & BMBS(hons). I have entered the Respiratory Medicine training programme in the Thames Valley deanery with plans to return to training after completion of my DPhil.
Recent publications
-
Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials
Voysey M. et al, (2021), The Lancet, 397, 881 - 891
-
Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK
Voysey M. et al, (2021), The Lancet, 397, 99 - 111
-
Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (COV002): a single-blind, randomised, controlled, phase 2/3 trial
Ramasamy MN. et al, (2020), The Lancet, 396, 1979 - 1993
-
Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial
Folegatti PM. et al, (2020), The Lancet, 396, 467 - 478
-
Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial (vol 396, pg 467, 2020)
Folegatti PM. et al, (2020), LANCET, 396, 466 - 466